Watch Ticker

vTv Therapeutics Inc. Class A Common Stock

Go to vTv Therapeutics Inc. Class A Common Stock Website

$14.62

0.14 (0.99%)

Live

Previous Close

$14.4737

Day Range

$14.6177 - $14.6177

Previous Day Range

$14.4737 - $14.75

Market Cap

$38.1 million USD

Day Vol.

284

Previous Day Vol.

556

Currency

USD

Primary Exchange

Nasdaq

vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its p...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

vTv Therapeutics has appointed Michael Tung as its new Chief Financial Officer. The company has also reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for the treatment of type 1 diabetes.

Related tickers: VTVT.

Read Full Article

Researchandmarkets.Com - 7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - Synergistic Rise of Pumps, CGMs, and Ultra-rapid-acting Insulins in T1D Management

The type 1 diabetes (T1D) market is expected to grow at a strong CAGR of 13.3% from 2023 to 2033, reaching $9.91 billion. Key drivers include the increased use of rapid-acting insulins, insulin pumps, and immunomodulatory therapies, as well as the rising global prevalence of T1D. However, high prices, patent expiries, and the failure of disease-modifying therapies in clinical trials pose challenges to market growth.

Related tickers: NVO, LLY, SNY, AZN, LXRX, FUJIY, NVS, MRK, ALPMY, AMGN, VTVT, BMY, CELGr, ADOCY, JNJ.

Read Full Article

Trending Tickers

Please sign in to view